Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic Adipose MSCs in Severe Systemic Sclerosis
NCT06722105Phase 2Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Dec 2024
- Primary completion
- Apr 2026
- Modality
- Stem Cell Therapies
01
Overview
Phase 2, randomised, double-blind trial of allogeneic adipose-derived mesenchymal stromal cells in systemic sclerosis (SSc) (3 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Rate of treatment-related Serious Adverse Events. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
allogeneic adipose-derived mesenchymal stromal cells
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT06722105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06722105.